Teva Pharmaceutical Appoints Eric Hughes As Chief Medical Officer

RTTNews | Pred 1155 dňami
Stocktwits
Teva Pharmaceutical Appoints Eric Hughes As Chief Medical Officer

(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) announced Friday the appointment of Dr. Eric Hughes, MD, PhD as Executive Vice President, Global R&D and Chief Medical Officer. Hughes will begin his employment on August 1, 2022, and will be based out of Teva's U.S. headquarters in Parsippany, New Jersey.

Hughes joins Teva with nearly 20 years of experience in all phases of drug development in leading global pharmaceutical companies, most recently as Senior Vice President of Clinical Development and Translational Medicine at Vertex Pharmaceuticals. Prior to that, he was Head of the Immunology, Hepatology & Dermatology Global Development Unit at Novartis.

He launched his career in the pharmaceutical industry in 2004, in early clinical research at Bristol Myers-Squibb Co. and then at Schering-Plough Research Institute.

Značky: TEVA
Stocktwits
read more
UroGen Pharma Files Patent Infringement Lawsuit Against Teva Pharma

UroGen Pharma Files Patent Infringement Lawsuit Against Teva Pharma

Biotech company UroGen Pharma Ltd. (URGN) announced Wednesday that it has filed a lawsuit in the U.S. District Court for the District of Delaware against Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., and Teva Pharmaceutical Industries, Ltd. (TEVA), alleging infringement of U.S. Patent Numbers 9,040,074 and 9,950,069.
RTTNews | Pred 513 dňami
Teva Pharmaceuticals Says Generic Version Of Forteo Approved In U.S

Teva Pharmaceuticals Says Generic Version Of Forteo Approved In U.S

Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced Friday the approval of a generic version of Forteo in the United States. Forteo had annual sales of $609 million as of July 2023, according to IQVIA data.
RTTNews | Pred 651 dňami
Teva Pharma Boosts FY23 Revenue Outlook - Update

Teva Pharma Boosts FY23 Revenue Outlook - Update

While reporting financial results for the third quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) reaffirmed its adjusted earnings guidance for the full-year 2023, while raising annual revenue outlook.
RTTNews | Pred 660 dňami
Teva Pharma Boosts FY23 Revenue Outlook - Update

Teva Pharma Boosts FY23 Revenue Outlook - Update

While reporting financial results for the second quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) reaffirmed its adjusted earnings guidance for the full-year 2023, while raising annual revenue outlook.
RTTNews | Pred 758 dňami
Teva Pharma Reaffirms FY23 Outlook - Update

Teva Pharma Reaffirms FY23 Outlook - Update

While reporting financial results for the first quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) reaffirmed its adjusted earnings and revenue guidance for the full-year 2023.
RTTNews | Pred 842 dňami
Teva Recalls FENTANYL Buccal Tablets CII

Teva Recalls FENTANYL Buccal Tablets CII

Teva Pharmaceuticals USA is recalling specific lots of various strengths of FENTANYL Buccal Tablets CII to the consumer level citing a labeling error, the U.S. Food and Drug Administration said. The recall has been initiated because safety updates were omitted in the product insert/medication guide that are provided with these recalled lots.
RTTNews | Pred 851 dňami
FTSE 100 Weak Again, Looks Headed For Weekly Loss

FTSE 100 Weak Again, Looks Headed For Weekly Loss

U.K. stocks are trading lower on Friday, losing ground for a fourth straight session, weighed down to a large extent by the weakness in the financial sector, amid reports of likely imposition of windfall tax on banks.
RTTNews | Pred 21 minútami
Nástroje
Ekonomický kalendár
Otváracie hodiny trhu
Úrokové sadzby
Kalendár sviatkov
Forexový trh
Forex Volatilita
Korelácia Forexu
Novinky na Forexe
Analýza forexu
COT Údaje
Likvidita
Forex kalkulačky
Forex Tepelná mapa
Ekonomické ukazovatele
Komunita
Komunita
Systémy
Najpopulárnejšie systémy
Stratégie
Súťaže
Forexové grafy
Forexový sentiment
Indikátor Outlook
Recenzie
Brokeri
Proprietárne obchodné firmy
Služby VPS
Poskytovatelia signálu
Služby programovania EA
Partnerské programy
Služby brokera PAMM
Služby zľavového programu
Obchodné platformy
Odborní poradcovia
Kryptoburzy
Obchodné kurzy
Brokeri
Forex Spready
Ponuky Forex brokerov
Swapy Forex brokerov
Objem brokera Forexu
Propagačné akcie Forex Brokera
Tlačová Správa
Platforma
Miniaplikácie
Funkcie
API
RSS
Stock Portfolio
Affiliate Software
Rozšírené grafy
Podpora
Často kladené otázky
Pomoc
Kontaktuj nás
Nahlásiť chybu!
O
Blog
& copy; 2025 Myfxbook Ltd. Všetky práva vyhradené.
UPOZORNENIE NA VYSOKÉ RIZIKO: Obchodovanie s devízami prináša vysokú úroveň rizika, ktoré nemusí byť vhodné pre všetkých investorov. Páka vytvára ďalšie riziká a straty. Než sa rozhodnete obchodovať s devízami, dôkladne zvážte svoje investičné ciele, úroveň skúseností a toleranciu voči riziku. Môžete prísť o časť alebo všetky svoje počiatočné investície. Neinvestujte peniaze, ktoré si nemôžete dovoliť stratiť. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Všetky údaje a informácie sú poskytované „tak, ako sú“. iba na informačné účely a nie je určené na obchodné účely alebo rady. Výkonnosť v minulosti neznamená výkonnosť v budúcnosti.